Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5344 - Outcomes and prognostic factors for angiosarcoma: A 19-year single institution experience

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Site

Sarcoma

Presenters

Monica Chirila

Citation

Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299

Authors

M.E. Chirila1, D.T. Eniu2, N. Todor3, V.M. Nagy1, M.L. Galatir4, D. Coza5, V. Cernea1, D.L. Martin1, Z. Fekete1

Author affiliations

  • 1 Radiotherapy, Ion Chiricuta Oncology Institute-IOCN, 400015 - Cluj-Napoca/RO
  • 2 Surgery, University of Medicine and Pharmacy Cluj-Napoca, 400015 - Cluj-Napoca/RO
  • 3 Biostatistics, The Oncology Institute "Prof.Dr.Ion Chiricuta" Cluj-Napoca, 4000000 - Cluj-Napoca/RO
  • 4 Pathology, The Oncology Institute "Prof.Dr.Ion Chiricuta" Cluj-Napoca, 4000000 - Cluj-Napoca/RO
  • 5 Epidemiology, The Oncology Institute "Prof.Dr.Ion Chiricuta" Cluj-Napoca, 4000000 - Cluj-Napoca/RO
More

Resources

Abstract 5344

Background

Angiosarcoma is a rare malignancy, and the data about its clinicopathological features and prognostic factors are limited. The purpose of this study was to present a retrospective analysis of angiosarcoma patients treated at a single institution.

Methods

Clinical and pathological features of 41 patients treated in our institution between 1998 and 2016 were analyzed.

Results

Of the 41 patients included, 53.7% were women and 46,3% were men and median age was 60 (16-81). 34.1% cases were located in the soft tissues (ST) of the limbs or trunk, 24.4% in the viscera (V), 19.5% in the breast (B), 14.6% involved the head and neck (HN) and 7.3% in the bone (B). The overall survival (OS) at 5 years was 26% (IC: 15% - 42%), with a median survival of 14.9 months. For the 17.1% patients that were alive at the time of analysis, the median follow up was 60 months (16.1-222.1).The tumor sites for the 7 surivors involved B(4), ST(1), HN(1) and V(1). Radiation induced angiosarcoma was suspected in 17.1% patients. Chronic lymphedema was described/highly probable for 19.5% of the patients. Surgery(S) was performed in 82.9% cases, chemotherapy(CT) in 41.5% cases, and radiation therapy(RT) for 9.8% of cases. CT was more likely to be given to younger patients, but did not improve OS. The pathology report was uncertain for 39% cases at first examination. Superficial tumors (B, ST and HN) had a better OS than deep tumors (V,B) but not statistically significant (31%vs15%). Women had a significant better OS compared to men (36%vs16%, p = 0.02). OS at 5 years for patients under age 67 was 30%, and 17% for patients above 67 (p = 0.07). Tumor grade was assesed for 85.4% cases. Grade 1(G1) was found in 12.2%, G2 in 36.6% and G3 in 36.6% patients. Patients having G3 tumors had a lower OS, but not statistically significant. Relapse occured at 58.5% of the patients (from 1 to 4 episodes). Of all relapses, 68.3% occured locally, 7.3% regionally, and 48.8% were distant metastases. The most common metastatic sites were lung (7 cases), bone (4), skin (4) and liver (3).

Conclusions

Angiosarcoma is an agressive tumor that was often underrecognized, occuring in various sites. Women with history of radiotherapy or lymphedema are at higher risk, but have a better prognosis. Younger patients and lower grade seem to have a longer survival.

Clinical trial identification

Legal entity responsible for the study

Chirila Monica-Emilia.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.